Expression of the multidrug resistance-associated protein (MRP) gene in urothelial carcinomas. 1996

H Kubo, and T Sumizawa, and K Koga, and K Nishiyama, and Y Takebayashi, and Y Chuman, and T Furukawa, and S Akiyama, and Y Ohi
Institute for Cancer Research, Faculty of Medicine, Kagoshima University, Japan.

The intrinsic or acquired resistance of urothelial cancer to chemotherapy is one major obstacle to successful treatment. Generally, the expression level of P-glycoprotein in urothelial cancer is low, so we accordingly investigated the expression of multidrug resistance-associated protein (MRP). We examined the expression of MRP mRNA by means of slot-blotting samples of 11 renal pelvic and/or ureteral tumors, 33 bladder tumors, one lung metastasis from a ureter tumor, 7 non-cancerous urothelia from patients with transitional-cell carcinoma (TCC) and one urothelium from a patient with renal-cell carcinoma (RCC). We also estimated, by Southern blotting, whether or not the MRP gene was amplified in clinical specimens that overexpressed MRP mRNA. MRP was detected immunohistochemically using a polyclonal antibody against MRP. In all, 5 of 11 renal pelvic and/or ureter tumors (45.5%), 17 of 33 bladder tumors (51.5%) and 4 of 7 non-cancerous urothelia of TCC patients (57.1%) expressed more than 2-fold the MRP mRNA levels of drug-sensitive human KB cells. There was no significant difference in the MRP mRNA level between primary and recurrent tumors. Low-grade urothelial carcinomas (G1 and G2 TCCs) expressed significantly higher levels of MRP mRNA than the high-grade G3 TCC. The MRP gene was not amplified in urothelial carcinomas, irrespective of their expression levels of MRP mRNA. Immunohistochemically, MRP was located mainly on the plasma membrane, but also detected on the cytoplasm of cancer cells. MRP may be one mechanism responsible for intrinsic drug resistance in low-grade urothelial cancer.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D009693 Nucleic Acid Hybridization Widely used technique which exploits the ability of complementary sequences in single-stranded DNAs or RNAs to pair with each other to form a double helix. Hybridization can take place between two complimentary DNA sequences, between a single-stranded DNA and a complementary RNA, or between two RNA sequences. The technique is used to detect and isolate specific sequences, measure homology, or define other characteristics of one or both strands. (Kendrew, Encyclopedia of Molecular Biology, 1994, p503) Genomic Hybridization,Acid Hybridization, Nucleic,Acid Hybridizations, Nucleic,Genomic Hybridizations,Hybridization, Genomic,Hybridization, Nucleic Acid,Hybridizations, Genomic,Hybridizations, Nucleic Acid,Nucleic Acid Hybridizations
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D012334 RNA, Neoplasm RNA present in neoplastic tissue. Neoplasm RNA
D014571 Urologic Neoplasms Tumors or cancer of the URINARY TRACT in either the male or the female. Cancer of Urinary Tract,Urinary Tract Cancer,Urologic Cancer,Cancer of the Urinary Tract,Neoplasms, Urologic,Urinary Tract Neoplasms,Urological Cancer,Urological Neoplasms,Cancer, Urinary Tract,Cancer, Urologic,Cancer, Urological,Cancers, Urinary Tract,Cancers, Urologic,Cancers, Urological,Neoplasm, Urinary Tract,Neoplasm, Urologic,Neoplasm, Urological,Neoplasms, Urinary Tract,Neoplasms, Urological,Tract Neoplasm, Urinary,Tract Neoplasms, Urinary,Urinary Tract Cancers,Urinary Tract Neoplasm,Urologic Cancers,Urologic Neoplasm,Urological Cancers,Urological Neoplasm
D015139 Blotting, Southern A method (first developed by E.M. Southern) for detection of DNA that has been electrophoretically separated and immobilized by blotting on nitrocellulose or other type of paper or nylon membrane followed by hybridization with labeled NUCLEIC ACID PROBES. Southern Blotting,Blot, Southern,Southern Blot
D015152 Blotting, Northern Detection of RNA that has been electrophoretically separated and immobilized by blotting on nitrocellulose or other type of paper or nylon membrane followed by hybridization with labeled NUCLEIC ACID PROBES. Northern Blotting,Blot, Northern,Northern Blot,Blots, Northern,Blottings, Northern,Northern Blots,Northern Blottings

Related Publications

H Kubo, and T Sumizawa, and K Koga, and K Nishiyama, and Y Takebayashi, and Y Chuman, and T Furukawa, and S Akiyama, and Y Ohi
January 1997, British journal of cancer,
H Kubo, and T Sumizawa, and K Koga, and K Nishiyama, and Y Takebayashi, and Y Chuman, and T Furukawa, and S Akiyama, and Y Ohi
January 1997, Anti-cancer drugs,
H Kubo, and T Sumizawa, and K Koga, and K Nishiyama, and Y Takebayashi, and Y Chuman, and T Furukawa, and S Akiyama, and Y Ohi
November 1995, Clinical cancer research : an official journal of the American Association for Cancer Research,
H Kubo, and T Sumizawa, and K Koga, and K Nishiyama, and Y Takebayashi, and Y Chuman, and T Furukawa, and S Akiyama, and Y Ohi
January 1996, Anticancer research,
H Kubo, and T Sumizawa, and K Koga, and K Nishiyama, and Y Takebayashi, and Y Chuman, and T Furukawa, and S Akiyama, and Y Ohi
January 2002, Leukemia & lymphoma,
H Kubo, and T Sumizawa, and K Koga, and K Nishiyama, and Y Takebayashi, and Y Chuman, and T Furukawa, and S Akiyama, and Y Ohi
April 1996, International journal of cancer,
H Kubo, and T Sumizawa, and K Koga, and K Nishiyama, and Y Takebayashi, and Y Chuman, and T Furukawa, and S Akiyama, and Y Ohi
February 1998, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
H Kubo, and T Sumizawa, and K Koga, and K Nishiyama, and Y Takebayashi, and Y Chuman, and T Furukawa, and S Akiyama, and Y Ohi
September 2000, Journal of neuro-oncology,
H Kubo, and T Sumizawa, and K Koga, and K Nishiyama, and Y Takebayashi, and Y Chuman, and T Furukawa, and S Akiyama, and Y Ohi
August 1995, Cancer letters,
H Kubo, and T Sumizawa, and K Koga, and K Nishiyama, and Y Takebayashi, and Y Chuman, and T Furukawa, and S Akiyama, and Y Ohi
October 1996, Biochemical pharmacology,
Copied contents to your clipboard!